{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T01:53:03Z","timestamp":1793411583207,"version":"4.5.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,6,24]],"date-time":"2021-06-24T00:00:00Z","timestamp":1624492800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,6,24]],"date-time":"2021-06-24T00:00:00Z","timestamp":1624492800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Glycation is a non-enzymatic process involving the reaction of reducing sugars or reactive oxoaldehyde with proteins, lipids or nucleic acids, which results in the formation of advanced glycation end\u00a0products (AGEs). The presented work discusses the glycation process in people with advanced stage of type 1 or type 2 diabetes. The concentration of different AGEs and their receptors for 58 serum samples was determined by ELISA and by spectrofluorimetric methods. In addition to fluorescent low molecular weight and protein-bound AGEs, we have also marked a new class of AGEs: melibiose-derived glycation product (MAGE). Our attention was also focused on the two groups of AGEs receptors: scavenger receptors (SR-A and SR-B) and RAGE. The correlation between the SR-AI scavenging receptors concentration and the fluorescence of AGEs as well as diabetes biological markers: GFR, creatinine contentration and HbA1c was demonstrated. A relationship between the concentration of AGEs and their receptors was also found in serum sample of patients treated with the metformin and aspirin. Furthermore, the concentration of SR-AI scavenger and the fluorescence of total AGEs was significantly lower in treated patients than in non treated patients. AGEs have also been found to contribute to the development of cardiovascular disease, atherosclerosis and diabetic complications, what could be deduced from the correlation of AGEs level and HDL cholesterol or uric acid level. Thus, it was confirmed that AGEs are involved in the pathomechanism of diabetes and other degenerative diseases. Nowadays, it is believed that AGEs due to the long time remaining in the body may be an important diagnostic marker. Their determination may allow monitoring the progression of the disease and the effectiveness of the therapy.<\/jats:p>","DOI":"10.1038\/s41598-021-92630-0","type":"journal-article","created":{"date-parts":[[2021,6,24]],"date-time":"2021-06-24T10:02:56Z","timestamp":1624528976000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":101,"title":["Advanced glycation end products and their receptors in serum of patients with type 2 diabetes"],"prefix":"10.1038","volume":"11","author":[{"given":"Diana","family":"Indyk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnieszka","family":"Bronowicka-Szyde\u0142ko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrzej","family":"Gamian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Kuzan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,24]]},"reference":[{"key":"92630_CR1","doi-asserted-by":"publisher","first-page":"259","DOI":"10.4161\/derm.22028","volume":"4","author":"P Gkogkolou","year":"2012","unstructured":"Gkogkolou, P. & B\u00f6hm, M. Advanced glycation end products: Keyplayers in skin aging?. Dermato-Endocrinol. 4, 259 (2012).","journal-title":"Dermato-Endocrinol."},{"key":"92630_CR2","first-page":"188","volume":"58","author":"MN Ahmad","year":"2020","unstructured":"Ahmad, M. N., Farh, A. I. & Al-Qirim, T. M. The cardiovascular complications of diabetes: a striking link through protein glycation. Rom. J. Intern. Med. 58, 188 (2020).","journal-title":"Rom. J. Intern. Med."},{"key":"92630_CR3","doi-asserted-by":"publisher","DOI":"10.1002\/mnfr.201900934","author":"D Sergi","year":"2020","unstructured":"Sergi, D., Boulestin, H., Campbell, F. M. & Williams, L. M. The role of dietary advanced glycation end products in metabolic dysfunction. Mol. Nutr. Food Res. https:\/\/doi.org\/10.1002\/mnfr.201900934 (2020).","journal-title":"Mol. Nutr. Food Res."},{"key":"92630_CR4","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.patbio.2009.09.014","volume":"58","author":"FJ La Tessier","year":"2010","unstructured":"La Tessier, F. J. r\u00e9action de Maillard dans le corps humain. D\u00e9couvertes majeures et facteurs qui affectent la glycation. Pathol. Biol. 58, 214\u2013219 (2010).","journal-title":"Pathol. Biol."},{"key":"92630_CR5","doi-asserted-by":"crossref","unstructured":"Perrone, A., Giovino, A., Benny, J. & Martinelli, F. Advanced Glycation End Products (AGEs): biochemistry, signaling, analytical methods, and epigenetic effects. Oxidative Med. Cell. Longevity 2020, (2020).","DOI":"10.1155\/2020\/3818196"},{"key":"92630_CR6","doi-asserted-by":"crossref","unstructured":"Staniszewska, M. et al. The melibiose-derived glycation product mimics a unique epitope present in human and animal tissues. Sci. Rep. 11, 2940 (2021).","DOI":"10.1038\/s41598-021-82585-7"},{"key":"92630_CR7","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1017\/S0029665108006034","volume":"67","author":"K Ka\u0148kov\u00e1","year":"2008","unstructured":"Ka\u0148kov\u00e1, K. Diabetic threesome (hyperglycaemia, renal function and nutrition) and advanced glycation end products: evidence for the multiple-hit agent?. Proc. Nutr. Soc. 67, 60\u201374 (2008).","journal-title":"Proc. Nutr. Soc."},{"key":"92630_CR8","doi-asserted-by":"publisher","first-page":"147","DOI":"10.33549\/physiolres.931585","volume":"59","author":"Z Turk","year":"2010","unstructured":"Turk, Z. Glycotoxines, carbonyl stress and relevance to diabetes and its complications. Physiol. Res. 59, 147\u2013156 (2010).","journal-title":"Physiol. Res."},{"key":"92630_CR9","doi-asserted-by":"publisher","first-page":"e0121086","DOI":"10.1371\/journal.pone.0121086","volume":"10","author":"G Asciutto","year":"2015","unstructured":"Asciutto, G. et al. Low elastin content of carotid plaques is associated with increased risk of ipsilateral stroke. PLoS ONE 10, e0121086 (2015).","journal-title":"PLoS ONE"},{"key":"92630_CR10","doi-asserted-by":"crossref","unstructured":"Kida, Y., Saito, M., Shinohara, A., Soshi, S. & Marumo, K. Non-invasive skin autofluorescence, blood and urine assays of the advanced glycation end product (AGE) pentosidine as an indirect indicator of AGE content in human bone. BMC Musculoskelet. Disord. 20, 627 (2019).","DOI":"10.1186\/s12891-019-3011-4"},{"key":"92630_CR11","doi-asserted-by":"publisher","first-page":"2414","DOI":"10.1002\/jnr.21692","volume":"86","author":"J Qin","year":"2008","unstructured":"Qin, J., Goswami, R., Dawson, S. & Dawson, G. Expression of the receptor for advanced glycation end products in oligodendrocytes in response to oxidative stress. J. Neurosci. Res. 86, 2414\u20132422 (2008).","journal-title":"J. Neurosci. Res."},{"key":"92630_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2013\/403460","volume":"2013","author":"YK Chuah","year":"2013","unstructured":"Chuah, Y. K., Basir, R., Talib, H., Tie, T. H. & Nordin, N. Receptor for advanced glycation end products and its involvement in inflammatory diseases. Int. J. Inflamm. 2013, 1 (2013).","journal-title":"Int. J. Inflamm."},{"key":"92630_CR13","unstructured":"Pietkiewicz, J., Seweryn, E., Barty\u015b, A. & Gamian, A. Receptory ko\u0144cowych produkt\u00f3w zaawansowanej glikacji-znaczenie fi zjologiczne i kliniczne* Receptors for advanced glycation end products and their physiological and clinical significance. Postepy Hig. Med. Dosw. 10, 511\u2013523 (2008)."},{"key":"92630_CR14","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1016\/j.dsx.2020.07.036","volume":"14","author":"KA Adeshara","year":"2020","unstructured":"Adeshara, K. A., Bangar, N. S., Doshi, P. R., Diwan, A. & Tupe, R. S. Action of metformin therapy against advanced glycation, oxidative stress and inflammation in type 2 diabetes patients: 3 months follow-up study. Diabetes Metab. Syndr. Clin. Res. Rev. 14, 1449\u20131458 (2020).","journal-title":"Diabetes Metab. Syndr. Clin. Res. Rev."},{"key":"92630_CR15","doi-asserted-by":"publisher","first-page":"178","DOI":"10.3390\/cells4020178","volume":"4","author":"I Zani","year":"2015","unstructured":"Zani, I. et al. Scavenger receptor structure and function in health and disease. Cells 4, 178\u2013201 (2015).","journal-title":"Cells"},{"key":"92630_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4061\/2010\/646929","volume":"2010","author":"SL Stephen","year":"2010","unstructured":"Stephen, S. L. et al. Scavenger receptors and their potential as therapeutic targets in the treatment of cardiovascular disease. Int. J. Hypertens. 2010, 1\u201321 (2010).","journal-title":"Int. J. Hypertens."},{"key":"92630_CR17","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.redox.2013.12.016","volume":"2","author":"C Ott","year":"2014","unstructured":"Ott, C. et al. Role of advanced glycation end products in cellular signaling. Redox Biol. 2, 411\u2013429 (2014).","journal-title":"Redox Biol."},{"key":"92630_CR18","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.atherosclerosis.2011.03.017","volume":"217","author":"A Ji","year":"2011","unstructured":"Ji, A. et al. Scavenger receptor SR-BI in macrophage lipid metabolism. Atherosclerosis 217, 106\u2013112 (2011).","journal-title":"Atherosclerosis"},{"key":"92630_CR19","first-page":"1","volume":"2020","author":"Z Bao","year":"2020","unstructured":"Bao, Z. et al. Advanced glycation end products induce vascular smooth muscle cell-derived foam cell formation and transdifferentiate to a macrophage-like state. Mediators Inflamm. 2020, 1 (2020).","journal-title":"Mediators Inflamm."},{"key":"92630_CR20","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.neuroscience.2020.11.003","volume":"453","author":"AM Dobri","year":"2021","unstructured":"Dobri, A. M., Dud\u0103u, M., Enciu, A. M. & Hinescu, M. E. CD36 in Alzheimer\u2019s disease: an overview of molecular mechanisms and therapeutic targeting. Neuroscience 453, 301\u2013311 (2021).","journal-title":"Neuroscience"},{"key":"92630_CR21","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1002\/cphy.c170026","volume":"8","author":"V Cifarelli","year":"2018","unstructured":"Cifarelli, V. & Abumrad, N. A. Intestinal CD36 and other key proteins of lipid utilization: role in absorption and gut homeostasis. Compr. Physiol. 8, 493\u2013507 (2018).","journal-title":"Compr. Physiol."},{"key":"92630_CR22","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1490003","author":"J El Khoury Post","year":"2021","unstructured":"El Khoury Post, J. et al. Nomenclature Standardizing Scavenger. Receptor https:\/\/doi.org\/10.4049\/jimmunol.1490003 (2021).","journal-title":"Receptor"},{"key":"92630_CR23","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.tcb.2020.02.007","volume":"30","author":"Y Meng","year":"2020","unstructured":"Meng, Y., Heybrock, S., Neculai, D. & Saftig, P. Cholesterol handling in lysosomes and beyond. Trends Cell Biol. 30, 452\u2013466 (2020).","journal-title":"Trends Cell Biol."},{"key":"92630_CR24","doi-asserted-by":"crossref","unstructured":"Kuzan, A., Chwi\u0142kowska, A., Maksymowicz, K. & Bronowicka-Szyde\u0142ko, A. Advanced glycation end products as a source of artifacts in immunoenzymatic methods. Glycoconj J.\u00a035, 95\u2013103 (2018).","DOI":"10.1007\/s10719-017-9805-4"},{"key":"92630_CR25","doi-asserted-by":"publisher","first-page":"3406","DOI":"10.1016\/j.tetlet.2015.01.122","volume":"56","author":"MA Richardson","year":"2015","unstructured":"Richardson, M. A. et al. Inhibition and breaking of advanced glycation end-products (AGEs) with bis-2-aminoimidazole derivatives. Tetrahedron Lett. 56, 3406\u20133409 (2015).","journal-title":"Tetrahedron Lett."},{"key":"92630_CR26","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.3377","author":"Y Zhou","year":"2020","unstructured":"Zhou, Y., Chi, J., Lv, W. & Wang, Y. Obesity and diabetes as high-risk factors for severe coronavirus disease 2019 ( <scp>Covid<\/scp> -19). Diabetes. Metab. Res. Rev. https:\/\/doi.org\/10.1002\/dmrr.3377 (2020).","journal-title":"Diabetes. Metab. Res. Rev."},{"key":"92630_CR27","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.3390\/jcm10051022","volume":"10","author":"U Abramczyk","year":"2021","unstructured":"Abramczyk, U. & Kuzan, A. What every diabetologist should know about SARS-CoV-2: state of knowledge at the beginning of 2021. J. Clin. Med. 10, 1022 (2021).","journal-title":"J. Clin. Med."},{"key":"92630_CR28","doi-asserted-by":"publisher","first-page":"285","DOI":"10.5152\/eurasianjmed.2019.18434","volume":"51","author":"C Toprak","year":"2019","unstructured":"Toprak, C. & Yigitaslan, S. Alagebrium and complications of diabetes mellitus. Eurasian J. Med. 51, 285\u2013292 (2019).","journal-title":"Eurasian J. Med."},{"key":"92630_CR29","doi-asserted-by":"publisher","first-page":"147916412095862","DOI":"10.1177\/1479164120958625","volume":"17","author":"D Nagayama","year":"2020","unstructured":"Nagayama, D. et al. High hemoglobin glycation index is associated with increased systemic arterial stiffness independent of hyperglycemia in real-world Japanese population: a cross-sectional study. Diabetes Vasc. Dis. Res. 17, 147916412095862 (2020).","journal-title":"Diabetes Vasc. Dis. Res."},{"key":"92630_CR30","doi-asserted-by":"publisher","first-page":"95","DOI":"10.4137\/BMI.S38440","volume":"11","author":"SI Sherwani","year":"2016","unstructured":"Sherwani, S. I., Khan, H. A., Ekhzaimy, A., Masood, A. & Sakharkar, M. K. Significance of HbA1c test in diagnosis and prognosis of diabetic patients. Biomark. Insights 11, 95\u2013104 (2016).","journal-title":"Biomark. Insights"},{"key":"92630_CR31","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/1475-2840-7-29","volume":"7","author":"R Meerwaldt","year":"2008","unstructured":"Meerwaldt, R. et al. The clinical relevance of assessing advanced glycation endproducts accumulation in diabetes. Cardiovasc. Diabetol. 7, 29 (2008).","journal-title":"Cardiovasc. Diabetol."},{"key":"92630_CR32","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1007\/s13340-015-0244-9","volume":"7","author":"N Hussain","year":"2016","unstructured":"Hussain, N. Implications of using HBA1C as a diagnostic marker for diabetes. Diabetol. Int. 7, 18\u201324 (2016).","journal-title":"Diabetol. Int."},{"key":"92630_CR33","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.amjhyper.2006.08.009","volume":"20","author":"M McNulty","year":"2007","unstructured":"McNulty, M., Mahmud, A. & Feely, J. Advanced glycation end-products and arterial stiffness in hypertension. Am. J. Hypertens. 20, 242\u2013247 (2007).","journal-title":"Am. J. Hypertens."},{"key":"92630_CR34","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1007\/s12013-007-0039-0","volume":"49","author":"S Vasdev","year":"2007","unstructured":"Vasdev, S., Gill, V. & Singal, P. Role of advanced glycation end products in hypertension and atherosclerosis: therapeutic implications. Cell Biochem. Biophys. 49, 48\u201363 (2007).","journal-title":"Cell Biochem. Biophys."},{"key":"92630_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijerph17186936","volume":"17","author":"A Saz-Lara","year":"2020","unstructured":"Saz-Lara, A. et al. Are advanced glycation end products in skin associated with vascular dysfunction markers? A meta-analysis. Int. J. Environ. Res. Public Health 17, 1\u201314 (2020).","journal-title":"Int. J. Environ. Res. Public Health"},{"key":"92630_CR36","doi-asserted-by":"publisher","first-page":"48","DOI":"10.4239\/wjd.v1.i2.48","volume":"1","author":"PK Dabla","year":"2010","unstructured":"Dabla, P. K. Renal function in diabetic nephropathy. World J. Diabetes 1, 48 (2010).","journal-title":"World J. Diabetes"},{"key":"92630_CR37","doi-asserted-by":"publisher","first-page":"3744","DOI":"10.2337\/db16-0310","volume":"65","author":"PJ Saulnier","year":"2016","unstructured":"Saulnier, P. J. et al. Advanced glycation end products predict loss of renal function and correlate with lesions of diabetic kidney disease in American indians with type 2 diabetes. Diabetes 65, 3744\u20133753 (2016).","journal-title":"Diabetes"},{"key":"92630_CR38","doi-asserted-by":"publisher","first-page":"F645","DOI":"10.1152\/ajprenal.00398.2004","volume":"289","author":"JM Bohlender","year":"2005","unstructured":"Bohlender, J. M., Franke, S., Stein, G. & Wolf, G. Advanced glycation end products and the kidney. Am. J. Physiol. Renal Physiol. 289, F645 (2005).","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"92630_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3164\/jcbn.15-3","volume":"57","author":"MS Ottum","year":"2015","unstructured":"Ottum, M. S. & Mistry, A. M. Advanced glycation end-products: Modifiable environmental factors profoundly mediate insulin resistance. J. Clin. Biochem. Nutr. 57, 1\u201312 (2015).","journal-title":"J. Clin. Biochem. Nutr."},{"key":"92630_CR40","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.cardfail.2006.11.009","volume":"13","author":"Y Koyama","year":"2007","unstructured":"Koyama, Y. et al. High serum level of pentosidine, an advanced glycation end product (AGE), is a risk factor of patients with heart failure. J. Card. Fail. 13, 199\u2013206 (2007).","journal-title":"J. Card. Fail."},{"key":"92630_CR41","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.lab.2005.12.006","volume":"147","author":"MP Cohen","year":"2006","unstructured":"Cohen, M. P., Ziyadeh, F. N. & Chen, S. Amadori-modified glycated serum proteins and accelerated atherosclerosis in diabetes: Pathogenic and therapeutic implications. J. Lab. Clin. Med. 147, 211\u2013219 (2006).","journal-title":"J. Lab. Clin. Med."},{"key":"92630_CR42","doi-asserted-by":"publisher","first-page":"S23","DOI":"10.1016\/j.amjhyper.2004.08.022","volume":"17","author":"GL Bakris","year":"2004","unstructured":"Bakris, G. L. et al. Advanced glycation end-product cross-link breakers: a novel approach to cardiovascular pathologies related to the aging process. Am. J. Hypertens. 17, S23\u2013S30 (2004).","journal-title":"Am. J. Hypertens."},{"key":"92630_CR43","doi-asserted-by":"publisher","first-page":"e74302","DOI":"10.1371\/journal.pone.0074302","volume":"8","author":"S Raposeiras-Roub\u00edn","year":"2013","unstructured":"Raposeiras-Roub\u00edn, S. et al. Fluorescent advanced glycation end products and their soluble receptor: the birth of new plasmatic biomarkers for risk stratification of acute coronary syndrome. PLoS ONE 8, e74302 (2013).","journal-title":"PLoS ONE"},{"key":"92630_CR44","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1093\/eurjhf\/hfq117","volume":"12","author":"S Raposeiras-Roub\u00edn","year":"2010","unstructured":"Raposeiras-Roub\u00edn, S. et al. Soluble receptor of advanced glycation end products levels are related to ischaemic aetiology and extent of coronary disease in chronic heart failure patients, independent of advanced glycation end products levels. Eur. J. Heart Fail. 12, 1092\u20131100 (2010).","journal-title":"Eur. J. Heart Fail."},{"key":"92630_CR45","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/j.jstrokecerebrovasdis.2010.10.004","volume":"21","author":"T Ikeda","year":"2012","unstructured":"Ikeda, T. et al. Serum pentosidine, an advanced glycation end product, indicates poor outcomes after acute ischemic stroke. J. Stroke Cerebrovasc. Dis. 21, 386\u2013390 (2012).","journal-title":"J. Stroke Cerebrovasc. Dis."},{"key":"92630_CR46","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.mehy.2008.03.020","volume":"71","author":"S Yamagishi","year":"2008","unstructured":"Yamagishi, S., Matsui, T. & Nakamura, K. Possible involvement of tobacco-derived advanced glycation end products (AGEs) in an increased risk for developing cancers and cardiovascular disease in former smokers. Med. Hypotheses 71, 259\u2013261 (2008).","journal-title":"Med. Hypotheses"},{"key":"92630_CR47","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.molmet.2013.11.006","volume":"3","author":"A Stirban","year":"2014","unstructured":"Stirban, A., Gawlowski, T. & Roden, M. Vascular effects of advanced glycation endproducts: clinical effects and molecular mechanisms. Mol. Metab. 3, 94\u2013108 (2014).","journal-title":"Mol. Metab."},{"key":"92630_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12986-018-0306-7","volume":"15","author":"JH Chen","year":"2018","unstructured":"Chen, J. H., Lin, X., Bu, C. & Zhang, X. Role of advanced glycation end products in mobility and considerations in possible dietary and nutritional intervention strategies. Nutr. Metab. 15, 1\u201318 (2018).","journal-title":"Nutr. Metab."},{"key":"92630_CR49","doi-asserted-by":"publisher","first-page":"123","DOI":"10.4110\/in.2013.13.4.123","volume":"13","author":"B Hyun","year":"2013","unstructured":"Hyun, B. et al. Metformin down-regulates TNF-\u03b1 secretion via suppression of scavenger receptors in macrophages. Immune Netw. 13, 123 (2013).","journal-title":"Immune Netw."},{"key":"92630_CR50","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.diabres.2006.12.024","volume":"77","author":"P Urios","year":"2007","unstructured":"Urios, P., Grigorova-Borsos, A. M. & Sternberg, M. Aspirin inhibits the formation of pentosidine, a cross-linking advanced glycation end product, in collagen. Diabetes Res. Clin. Pract. 77, 337\u2013340 (2007).","journal-title":"Diabetes Res. Clin. Pract."},{"key":"92630_CR51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms21186842","volume":"21","author":"YA Nasykhova","year":"2020","unstructured":"Nasykhova, Y. A., Tonyan, Z. N., Mikhailova, A. A., Danilova, M. M. & Glotov, A. S. Pharmacogenetics of type 2 diabetes\u2014progress and prospects. Int. J. Mol. Sci. 21, 1\u201326 (2020).","journal-title":"Int. J. Mol. Sci."},{"key":"92630_CR52","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.vph.2018.02.001","volume":"103\u2013105","author":"MH Yu","year":"2018","unstructured":"Yu, M. H., Lin, M. C., Huang, C. N., Chan, K. C. & Wang, C. J. Acarbose inhibits the proliferation and migration of vascular smooth muscle cells via targeting Ras signaling. Vascul. Pharmacol. 103\u2013105, 8\u201315 (2018).","journal-title":"Vascul. Pharmacol."},{"key":"92630_CR53","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/s10238-009-0074-9","volume":"10","author":"M Tsunosue","year":"2010","unstructured":"Tsunosue, M. et al. An a-glucosidase inhibitor, acarbose treatment decreases serum levels of glyceraldehyde-derived advanced glycation end products (AGEs) in patients with type 2 diabetes. Clin. Exp. Med. 10, 139\u2013141 (2010).","journal-title":"Clin. Exp. Med."},{"key":"92630_CR54","unstructured":"Leszek, J., Ferens-Sieczkowska, M. & K\u0105tnik-Prastowska, I. Fluorescent advanced glycation end products in the sera of Alzheimer\u2019s disease patients. Perspect. Neurosci. Mem. Profr. Agapitos Diacoyannis 373\u2013381 (2005)."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-92630-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-92630-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-92630-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,4]],"date-time":"2023-02-04T06:16:53Z","timestamp":1675491413000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-92630-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,24]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["92630"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-92630-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,24]]},"assertion":[{"value":"23 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"13264"}}